RxDoctor Payments Data

Andrew Korman, MD

Gastroenterology · New Brunswick, NJNPI 1780833343

Payments from drug & device makers

$2,898in general payments, 2019–2025

Across 128 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boston Scientific$790
  • Johnson & Johnson$266
  • Takeda Pharmaceuticals U.S.A., Inc.$162
  • Olympus America Inc.$101
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
  • plus $217 from 11 others

What the payments were for

  • Speaking & faculty fees$40014%
  • Food & beverage$2,36782%
  • Education$1315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,898 in reported general payments places this provider in the 50th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$155,669
Medicare patients
458
Services billed
1,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase31$55,379
XifaxanRifaximin17$54,777
LinzessLinaclotide52$42,215
Dexlansoprazole DrDexlansoprazole51$11,617
Lactulose24$9,873
Mesalamine19$7,023
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates90$5,969
Pantoprazole Sodium217$5,092
Lubiprostone27$4,895
NexiumEsomeprazole Magnesium15$3,862
Sucralfate15$2,806
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,742
Omeprazole186$2,402
Ondansetron Hcl23$1,422
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,291$97,59483 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$70$54,77717 claims
Braintree Laboratories, Inc.Sutab$13$2,74217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →